Comparative study of antiretroviral drug regimens and drug–drug interactions between younger and older HIV-infected patients at a tertiary care teaching hospital in South Korea

References

• OguntibejuOOQuality of life of people living with HIV and AIDS and antiretroviral therapyHIV AIDS20124117124
   Google Scholar
• MaggiPDi BiagioARusconiSCardiovascular risk and dyslipidemia among persons living with HIV: a reviewBMC Infect Dis201717155128793863
   PubMed Web of Science ®Google Scholar
• MahyMAutenriethCSStaneckiKWyndSIncreasing trends in HIV prevalence among people aged 50 years and older: evidence from estimates and survey dataAIDS201428Suppl 4S453S45925222641
   PubMed Web of Science ®Google Scholar
• HoltzmanCArmonCTedaldiEPolypharmacy and risk of antiretroviral drug interactions among the aging HIV-infected populationJ Gen Intern Med201328101302131023605401
   PubMed Web of Science ®Google Scholar
• LinCFWangCYBaiCHPolypharmacy, aging and potential drug-drug interactions in outpatients in Taiwan: a retrospective computerized screening studyDrugs Aging201128321922521250763
   PubMed Web of Science ®Google Scholar
• SecoliSRFiguerasALebrãoMLde LimaFDSantosJLRisk of potential drug-drug interactions among Brazilian elderly: a population-based, cross-sectional studyDrugs Aging201027975977020809665
   PubMed Web of Science ®Google Scholar
• McNichollIRGandhiMHareCBGreeneMPierluissiEA pharmacist-led program to evaluate and reduce polypharmacy and potentially inappropriate prescribing in older HIV-positive patientsPharmacotherapy201737121498150629023938
   PubMed Web of Science ®Google Scholar
• Cantudo-CuencaMRJiménez-GalánRAlmeida-GonzalezCVMorillo-VerdugoRConcurrent use of comedications reduces adherence to antiretroviral therapy among HIV-infected patientsJ Manag Care Spec Pharm201420884485025062078
   PubMedGoogle Scholar
• BaeckeCGyssensICDecoutereLvan der HilstJCHMessiaenPPrevalence of drug-drug interactions in the era of HIV integrase inhibitors: a retrospective clinical studyNeth J Med201775623524028741582
   PubMed Web of Science ®Google Scholar
• TsengASzadkowskiLWalmsleySSalitIRaboudJAssociation of age with polypharmacy and risk of drug interactions with antiretroviral medications in HIV-positive patientsAnn Pharmacother201347111429143924285760
   PubMed Web of Science ®Google Scholar
• BastidaCGrauAMárquezMPolypharmacy and potential drug-drug interactions in an HIV-infected elderly populationFarm Hosp201741561862428847251
   PubMed Web of Science ®Google Scholar
• SmithJMFlexnerCThe challenge of polypharmacy in an aging population and implications for future antiretroviral therapy developmentAIDS201731Suppl 2S173S18428471948
   PubMed Web of Science ®Google Scholar
• MolasELuqueSRetameroAFrequency and severity of potential drug interactions in a cohort of HIV-infected patients identified through a multidisciplinary teamHIV Clin Trials20181911729179644
   PubMed Web of Science ®Google Scholar
• GhideiLSimoneMJSalowMJAging, antiretrovirals, and adherence: a meta analysis of adherence among older HIV-infected individualsDrugs Aging2013301080981923959913
   PubMed Web of Science ®Google Scholar
• AIDSinfoGuidelines for the use of antiretroviral agents in adults and adolescents living with HIV Available from: https://aidsinfo.nih.gov/guidelines/html/1/adult-and-adolescent-arv/0Accessed April 4, 2018
   Google Scholar
• World Health OrganizationConsolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection: recommendations for a public health approach – second edition2016 Available from: http://www.who.int/hiv/pub/arv/arv-2016/en/Accessed April 4, 2018
   Google Scholar
• Liverpool HIV Drug Interactions [homepage on the Internet] Available from: https://www.hiv-druginteractions.org/Accessed September 6, 2018
   Google Scholar
• EscotaGVO’HalloranJAPowderlyWGPrestiRMUnderstanding mechanisms to promote successful aging in persons living with HIVInt J Infect Dis201866566429154830
   PubMed Web of Science ®Google Scholar
• Güerri-FernandezRVestergaardPCarbonellCHIV infection is strongly associated with hip fracture risk, independently of age, gender, and comorbidities: a population-based cohort studyJ Bone Miner Res20132861259126323362011
   PubMed Web of Science ®Google Scholar
• PalellaFJBakerRKMoormanACMortality in the highly active antiretroviral therapy era: changing causes of death and disease in the HIV outpatient studyJ Acquir Immune Defic Syndr2006431273416878047
   PubMed Web of Science ®Google Scholar
• COMBIVIR®Package Insert Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/20857s030lbl.pdfAccessed April 11, 2018
   Google Scholar
• FlynnPMRodmanJLindseyJCIntracellular pharmacokinetics of once versus twice daily zidovudine and lamivudine in adolescentsAntimicrob Agents Chemother200751103516352217664328
   PubMed Web of Science ®Google Scholar
• RuanePJRichmondGJDejesusEPharmacodynamic effects of zidovudine 600 mg once/day versus 300 mg twice/day in therapy-naïve patients infected with human immunodeficiency virusPharmacotherapy200424330731215040643
   PubMed Web of Science ®Google Scholar
• STRIBILD®Package Insert Available from: https://www.gilead.com/~/media/files/pdfs/medicines/hiv/stribild/stribild_pi.pdf?la=enAccessed April 11, 2018
   Google Scholar
• GENVOYA®Package Insert Available from: https://www.gilead.com/~/media/files/pdfs/medicines/hiv/genvoya/genvoya_pi.pdf?la=enAccessed April 11, 2018
   Google Scholar
• TRIUMEQ®Package Insert Available from: https://www.viivhealthcare.com/media/80846/Triumeq-PI-MG.pdfAccessed April 11, 2018
   Google Scholar
• GallantJEDejesusEArribasJRTenofovir DF, emtricitabine, and efavirenz vs. zidovudine, lamivudine, and efavirenz for HIVN Engl J Med2006354325126016421366
   PubMed Web of Science ®Google Scholar
• PozniakALGallantJEDejesusETenofovir Disoproxil Fumarate, emtricitabine, and efavirenz versus fixed-dose zidovudine/lamivudine and efavirenz in antiretroviral-naive patients: virologic, immunologic, and morphologic changes-a 96-week analysisJ Acquir Immune Defic Syndr200643553554017057609
   PubMed Web of Science ®Google Scholar
• TruongWRSchaferJJShortWROnce-daily, single-tablet regimens for the treatment of HIV-1 infectionP&T2015401445525628507
   PubMedGoogle Scholar
• SebaalyJCKelleyDSingle-tablet regimens for the treatment of HIV-1 infectionAnn Pharmacother201751433234427895236
   PubMed Web of Science ®Google Scholar
• AngioneSACherianSMÖzdenerAEA review of the efficacy and safety of Genvoya® (elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide) in the Management of HIV-1 infectionJ Pharm Pract201831221622128558493
   PubMed Web of Science ®Google Scholar
• RaffiFOrkinCClarkeABrief Report: long-term (96-week) efficacy and safety after switching from tenofovir disoproxil fumarate to tenofovir alafenamide in HIV-infected, virologically suppressed adultsJ Acquir Immune Defic Syndr201775222623128272164
   PubMed Web of Science ®Google Scholar
• ArribasJRThompsonMSaxPEBrief report: randomized, double-blind comparison of tenofovir alafenamide (TAF) vs tenofovir disoproxil fumarate (TDF), each coformulated with elvitegravir, cobicistat, and emtricitabine (E/C/F) for initial HIV-1 treatment: Week 144 resultsJ Acquir Immune Defic Syndr201775221121828282300
   PubMed Web of Science ®Google Scholar
• SaxPEWohlDYinMTTenofovir alafenamide versus tenofovir disoproxil fumarate, coformulated with elvitegravir, cobicistat, and emtricitabine, for initial treatment of HIV-1 infection: two randomised, double-blind, phase 3, non-inferiority trialsLancet201538599872606261525890673
   PubMed Web of Science ®Google Scholar
• MillsAArribasJRAndrade-VillanuevaJSwitching from tenofovir disoproxil fumarate to tenofovir alafenamide in antiretroviral regimens for virologically suppressed adults with HIV-1 infection: a randomised, active-controlled, multicentre, open-label, phase 3, non-inferiority studyLancet Infect Dis2016161435226538525
   PubMed Web of Science ®Google Scholar
• DorjeeKBaxiSMReingoldALHubbardARisk of cardiovascular events from current, recent, and cumulative exposure to abacavir among persons living with HIV who were receiving antiretroviral therapy in the United States: a cohort studyBMC Infect Dis201717170829078761
   PubMed Web of Science ®Google Scholar
• MarzoliniCBackDWeberRAgeing with HIV: medication use and risk for potential drug-drug interactionsJ Antimicrob Chemother20116692107211121680580
   PubMed Web of Science ®Google Scholar